ROLE OF HEPATITIS B VIRUS IN HEPATOCELLULAR CARCINOMA

乙型肝炎病毒在肝细胞癌中的作用

• 批准号: 5201586
• 负责人: E TABOR
• 金额: --
• 依托单位: DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/5201586
• 关键词: antiviral antibody; gene mutation; hepatitis B virus group; hepatocellular carcinoma; human tissue; mathematical model; questionnaires; serology /serodiagnosis; surface antigens; viral carcinogenesis; virus antigen

Hepatitis B virus (HBV) with a stop mutation at precore codon 28 (TGG to TAG, tryptophan to stop) was investigated in the serum of hepatocellular carcinoma patients with hepatitis B surface antigen (73 from Korea; 14 of Japanese ancestry in Hawaii). Among these, hepatitis B virus DNA was detectable in 64 (88%) patients from Korea and 9 (64%) patients from Hawaii, using polymerase chain reaction. Among patients with direct sequencing results, this mutation was identified in 50/58 (86%) patients from Korea and 9/9 (100%) of those from Hawaii. Among patients with this mutant HBV, 21/50 (42%) patients from Korea and 1/9 (11%) from Hawaii were coinfected as well with wild-type HBV. The prevalence of the mutant virus (without co-infection with wild-type HBV) among patients with hepatitis B e antigen (23/28[82%]) was not different from that in patients without it (27/30 [90%]). Generally, it was expected that patients with hepatitis B e antigen would be infected with wild-type HBV and those without hepatitis B e antigen were expected to have the mutant HBV. However, 10/28 (36%) patients with hepatitis B e antigen had the mutant HBV alone. These data suggest that HBV with the precore codon 28 stop mutation may contribute to the development of hepatocellular carcinoma and this mutation often is not correlated with the absence of hepatitis B e antigen. During a 16-month period in 1991-1992, blood samples and questionnaire data were obtained from 65 incident cases of hepatocellular carcinoma (HCC) as well as from 2 control groups of hospitalized patients matched on gender and age, which included 65 metastatic liver cancer patients and 65 patients hospitalized for eye, ear, nose or throat conditions. The odds ratio (with 95% confidence intervals) in logistic regression modeling comparing the HCC cases to the combined control series were 18.8 (8.2-43.2) for the presence of hepatitis B surface antigen and 7.7 (1.7- 35.1) for antibody to the hepatitis C virus (anti-HCV).

在前C密码子28处具有终止突变（TGG至TGG）的B型肝炎病毒（HBV） TAG，色氨酸终止）在肝细胞癌患者血清中进行了研究 携带B型肝炎表面抗原的癌症患者（73例来自韩国; 14例来自 在夏威夷的日本血统）。 其中，B型肝炎病毒DNA是 在64例（88%）韩国患者和9例（64%） 夏威夷，使用聚合酶链反应。 在直接 测序结果显示，在50/58（86%）例患者中发现了该突变 来自韩国和9/9（100%）来自夏威夷。 在患有这种疾病的患者中， 突变型HBV，21/50例（42%）来自韩国，1/9例（11%）来自夏威夷 同时感染野生型HBV。 突变体的流行 病毒（不与野生型HBV共感染） B e抗原（23/28[82%]）与 未使用的患者（27/30 [90%]）。 一般来说，预计 携带B e抗原的患者可能感染野生型HBV 而那些没有B e型肝炎抗原的人则被认为有突变 乙肝病毒。 然而，10/28例（36%）携带B e抗原的患者有 单独突变HBV。 这些数据表明，HBV前C密码子28 终止突变可能有助于肝细胞癌的发生 这种突变通常与缺乏癌基因无关。 B e型肝炎抗原。 在1991-1992年的16个月期间， 资料来源于65例原发性肝癌 (HCC)以及来自2个对照组的匹配的住院患者 包括65例转移性肝癌患者， 65名患者因眼、耳、鼻或咽喉疾病住院。 的 logistic回归中的优势比（95%置信区间） HCC病例与联合对照系列的模型比较为18.8 （8.2-43.2）检测是否存在B型肝炎表面抗原，7.7（1.7- 35.1）丙型肝炎病毒抗体（抗HCV）。